Instead in the PO area, only LOPC treatment was found giving a significant contribution (p < 0.05), with a significant difference between stroke and LOPC at 30 days for both Iba1 and CD68 (p < 0.05) as assessed by post-hoc analysis. The gene discussed is CD68; the disease is stroke disorder.